BioCentury
ARTICLE | Clinical News

Emricasan: Phase II data

October 5, 2015 7:00 AM UTC

Top-line data from 22 evaluable patients with portal hypertension and compensated liver cirrhosis predominantly due to non-alcoholic steatohepatitis (NASH) or HCV infection in an open-label, U.S. Phas...